Increased production of a proliferation-inducing ligand (APRIL) by peripheral blood mononuclear cells is associated with antitopoisomerase I antibody and more severe disease in systemic sclerosis

Journal of Rheumatology

Volumn 37, Issue 11, 2010, Pages 2286-2289

  Bielecki, Marek ^a   Kowal, Krzysztof ^a   Lapinska, Anna ^a   Bernatowicz, Pawel ^a   Chyczewski, Lech ^a   Kowal Bielecka, Otylia ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

APRIL; Pathogenesis; Scleroderma; Systemic sclerosis

Indexed keywords

ANTIBODY; ANTITOPOISOMERASE I ANTIBODY; APRIL PROTEIN; AUTOANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CAPILLARY; CELL SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETAL CALF SERUM; HUMAN; HUMAN CELL; INTERSTITIAL LUNG DISEASE; MALE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; SCLERODERMA; SUPERNATANT; SYSTEMIC SCLEROSIS; UPREGULATION;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIBODIES, ANTI-IDIOTYPIC; CELLS, CULTURED; DNA TOPOISOMERASES, TYPE I; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 78149263201     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100454     Document Type: Article

References (14)

1. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006;18:263-75.
2. Ferrer G, Hodgson K, Montserrat E, Moreno C. B cell activator factor and a proliferation-inducing ligand at the cross-road of chronic lymphocytic leukemia and autoimmunity. Leuk Lymphoma 2009;50:1075-82.
3. Matsushita T, Fujimoto M, Hasegawa M, Tanaka C, Kumada S, Ogawa F, et al. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol 2007;34:2056-62.
4. Chizzolini C. T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis. Curr Opin Rheumatol 2008;20:707-12.
5. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
6. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
7. Bielecki M, Kowal K, Lapinska A, Chwiecko J, Skowronski J, Sierakowski S, et al. Diminished production of TWEAK by the peripheral blood mononuclear cells is associated with vascular involvement in patients with systemic sclerosis. Folia Histochem Cytobiol 2009:47:465-9.
8. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
9. Carpentier PH, Maricq HR. Microvasculature in systemic sclerosis. Rheum Dis Clin North Am 1990;16:75-91.
10. Cepeda EJ, Reveille JD. Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curr Opin Rheumatol 2004;16:723-32.
11. Koenig M, Dieudé M, Senécal JL. Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. Autoimmun Rev 2008;7:588-93.
12. Hanke K, Dähnrich C, Brückner CS, Huscher D, Becker M, Jansen A, et al. Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther 2009;11:R28.
13. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007;56:4142-50.
14. Bracewell C, Isaacs JD, Emery P, Ng WF. Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2009;9:909-19.